{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135733","form_type":"8-K","ticker":null,"cik":"0001744659","company_name":"Akero Therapeutics, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.861011+00:00","generated_at":"2026-06-02T04:00:12.338696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Akero Q1 2024 cash $903.7M; Phase 2b HARMONY week 96 fibrosis improvement 75% for 50mg EFX","bullets":["Cash, equivalents and short-term marketable securities $903.7M as of March 31, 2024; March equity offering raised ~$366.9M gross.","Phase 2b HARMONY Week 96: 75% (50mg) and 46% (28mg) achieved ≥1-stage fibrosis improvement without MASH worsening vs 24% placebo (p<0.001 and p=0.07).","36% (50mg) and 31% (28mg) showed 2-stage fibrosis improvement vs 3% placebo (p<0.01).","Total operating expenses $60.0M vs $28.8M YoY on increased R&D for Phase 3 studies.","Phase 3 SYNCHRONY Histology and Real-World enrolling; Outcomes trial on track to start Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135733","json":"https://secwatch.observer/filing/0001193125-24-135733.json","markdown":"https://secwatch.observer/filing/0001193125-24-135733.md","text":"https://secwatch.observer/filing/0001193125-24-135733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/0001193125-24-135733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/d836734d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:00:12.338696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf3a8eb03a16c0373684d6ebe624e2b5acb6e4d6","claim":"Akero Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 10, 2024, Akero Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/0001193125-24-135733-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}